Show simple item record

Typical Household Elasticity of Demand for Pharmaceuticals Across European States

dc.contributor.authorŻółtaszek, Agata
dc.date.accessioned2022-09-19T08:20:08Z
dc.date.available2022-09-19T08:20:08Z
dc.date.issued2022-08-22
dc.identifier.issn0208-6018
dc.identifier.urihttp://hdl.handle.net/11089/43248
dc.description.abstractAccording to the World Health Organisation (WHO), almost a billion people worldwide are at risk of falling into poverty due to out‑of‑pocket health spending, and pharmaceuticals are an integral part of this growing problem. The presented study aims to assess the price and income elasticity of demand for pharmaceuticals across European states over the period 2009–2019. The subject of the analysis is a typical household in each state. The analysis focuses on evaluating interactions in the light of economic growth, thus the results are cross‑referenced with the countries’ development groups to pinpoint any similarities and contrasts within and between clusters. The results indicate that households in underprivileged regions have a higher responsiveness to economic stimuli than in prosperous states. Both the income and price elasticities indicate the existence of unmet need for pharmaceuticals due to insufficient financial resources. Moreover, households’ responsiveness to income and price changes varies across time, states and affluence development groups.en
dc.description.abstractWedług Światowej Organizacji Zdrowia (WHO) prawie miliard ludzi na całym świecie jest zagrożonych popadnięciem w ubóstwo z powodu wydatków na zdrowie, a farmaceutyki są integralną częścią rosnącego problemu. Niniejsze badanie ma na celu ocenę elastyczności cenowej i dochodowej popytu na leki w państwach europejskich w latach 2009–2019. Przedmiotem analizy jest typowe gospodarstwo domowe w każdym kraju. Analiza koncentruje się na ocenie problemu w świetle wzrostu gospodarczego. W związku z tym wyniki są porównywane według grup rozwoju krajów, aby wskazać wszelkie podobieństwa i różnice wewnątrz klastrów i między nimi. Wyniki wskazują, że gospodarstwa domowe w regionach biedniejszych są bardziej wrażliwe na bodźce ekonomiczne niż w krajach zamożnych. Zarówno elastyczność dochodowa, jak i cenowa wskazują na niezaspokojone zapotrzebowanie na leki z powodu niewystarczających zasobów finansowych. Co więcej, reakcja gospodarstw domowych na zmiany dochodów i cen różni się w zależności od czasu, kraju i klastrów.pl
dc.language.isoen
dc.publisherWydawnictwo Uniwersytetu Łódzkiegopl
dc.relation.ispartofseriesActa Universitatis Lodziensis. Folia Oeconomica;358en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjecthealth economicsen
dc.subjectout-of-pocket pharmaceutical expendituresen
dc.subjectincome elasticity of demanden
dc.subjectprice elasticity of demanden
dc.subjectregional studiesen
dc.subjectekonomia zdrowiapl
dc.subjectbezpośrednie prywatne wydatki farmaceutycznepl
dc.subjectdochodowa elastyczność popytupl
dc.subjectcenowa elastyczność popytupl
dc.subjectanalizy regionalnepl
dc.titleTypical Household Elasticity of Demand for Pharmaceuticals Across European Statesen
dc.title.alternativeElastyczność popytu na farmaceutyki typowego gospodarstwa domowego w krajach europejskichpl
dc.typeArticle
dc.page.number32-58
dc.contributor.authorAffiliationUniversity of Lodz, Faculty of Economics and Sociology, Department of Spatial Econometrics, Lodz, Polanden
dc.identifier.eissn2353-7663
dc.referencesAlghanim S.A. (2011), Self-medication practice among patients in a public health care system, “Eastern Mediterranean Health Journal”, vol. 17, no. 5, pp. 409–416.en
dc.referencesBen-Aharon O., Shavit O., Magnezi R. (2017), Does drug price-regulation affect healthcare expenditures?, “The European Journal of Health Economics”, vol. 18, pp. 859–867, https://doi.org/10.1007/s10198-016-0832-zen
dc.referencesBesanko D., Braeutigam R. (2013), Microeconomics, John Wiley & Sons, Hoboken.en
dc.referencesBhattacharya J., Hyde T., Tu P. (2013), Health Economics, Macmillan International Higher Education, New York.en
dc.referencesColorectal cancer burden in EU–27 (2021), European Cancer Information System, European Union, https://ecis.jrc.ec.europa.eu/pdf/Colorectal_cancer_factsheet-Mar_2021.pdf (accessed: 1.08.2021).en
dc.referencesDu J., Yang X., Chen M., Wang Z. (2019), Socioeconomic determinants of out-of-pocket pharmaceutical expenditure among middle-aged and elderly adults based on the China Health and Retirement Longitudinal Survey, “BMJ Open”, vol. 9, pp. 1–13, https://doi.org/10.1136/bmjopen-2018-024936en
dc.referencesDunphy C., Peterson C., Zhang K., Jones C.M. (2021), Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?, “Drug and Alcohol Dependence”, vol. 225, pp. 1–5, https://doi.org/10.1016/j.drugalcdep.2021.108784en
dc.referencesDwivedi D.N. (2002), Microeconomics: Theory And Applications, Pearson Education India, Delhi.en
dc.referencesEurostat (n.d.), Harmonised Indices of Consumer Prices (HICP) – FAQ, https://ec.europa.eu/eurostat/web/hicp/faq (accessed: 13.08.2021).en
dc.referencesEurostat (n.d.), Health care expenditure, https://ec.europa.eu/eurostat/cache/metadata/en/hlth_sha11_esms.htm (accessed: 13.08.2021).en
dc.referencesEurostat Database (n.d.), https://ec.europa.eu/eurostat/data/database (accessed: 1.08.2021).en
dc.referencesGazaway S.B., Barnett M.D., Bowman E.H., Ejem D., Harrell E.R., Brown C.J., Bakitas M. (2021), Health Professionals Palliative Care Education for Older Adults: Overcoming Ageism, Racism, and Gender Bias, “Current Geriatrics Reports”, no. 10, pp. 148–156, https://doi.org/10.1007/s13670-021-00365-7en
dc.referencesGlied S., Smith P.C. (2013), The Oxford Handbook of Health Economics, Oxford University Press, Oxford.en
dc.referencesGuinness L., Wiseman V . (2011), Introduction To Health Economics, McGraw-Hill Education, Berkshire.en
dc.referencesMacDonald M. (1995), Feminist economics: from theory to research, “Canadian Journal of Economics”, vol. 28, no. 1, pp. 159–176.en
dc.referencesMakowska M., Boguszewski R., Nowakowski M., Podkowińska M. (2020), Self-Medication-Related Behaviors and Poland’s COVID–19 Lockdown, “International Journal of Environmental Research and Public Health”, vol. 17, no. 8344, https://doi.org/10.3390/ijerph17228344en
dc.referencesMatin B.K., Azami S.R., Mahmoudi S., Rezaei S., Shaahmadi F., Karyani A.K. (2015), Determinants of pharmaceutical expenditures of urban households: A time series study in Kermanshah province (Iran), “Electron Physician”, vol. 7, no. 7, https://doi.org/10.19082/1470en
dc.referencesMcClellan C., Fingar K.R., Ali M.M., Olesiuk W.J., Mutterd R., Gibson T.B. (2019), Price elasticity of demand for buprenorphine/naloxone prescriptions, “Journal of Substance Abuse Treatment”, vol. 106, pp. 4–11, https://doi.org/10.1016/j.jsat.2019.08.001en
dc.referencesMurphy S.M., Morgan J.R., Jeng P.J., Schackman B.R. (2019), Will converting naloxone to over-the-counter status increase pharmacy sales?, “Health Services Research”, vol. 54, issue 4, pp. 764–772, https://doi.org/10.1111/1475-6773.13125en
dc.referencesO’Brien G.L., McAlister M., Byrne S., Gallagher J. (2020a), Overcoming hurdles: measurement of health-related outcomes associated with national level medicines usage in Ireland, “Drugs in Context”, vol. 9, no. 4–2, https://doi.org/10.7573/dic.2020-4-2en
dc.referencesO’Brien G.L., Sinnott S.-J., O’Flynn B., Walshe V., Mulcahy M., Byrne S. (2020b), Out of pocket or out of control: A qualitative analysis of healthcare professional stakeholder involvement in pharmaceutical policy change in Ireland, “Health Policy”, vol. 124, issue 4, pp. 411–418, https://doi.org/10.1016/j.healthpol.2020.02.011en
dc.referencesOECD (2003), Glossary of statistical terms, https://stats.oecd.org/glossary/ (accessed: 12.08.2021).en
dc.referencesOlsen J.A. (2017), Principles in Health Economics and Policy, Oxford University Press, Oxford.en
dc.referencesSanterre R.E., Vemont J.A. (2006), Assessing Consumer Gains from a Drug Price Control Policy in the United States, “Southern Economic Journal”, vol. 73(1), pp. 233–245.en
dc.referencesSanwald A., Theurl E. (2017), Out-of-pocket expenditures for pharmaceuticals: lessons from the Austrian household budget survey, “European Journal of Health Economics”, vol. 18, pp. 435–447, https://doi.org/10.1007/s10198-016-0797-yen
dc.referencesSiminski P. (2011), The price elasticity of demand for pharmaceuticals amongst high income older Australians: a natural experiment, “Applied Economics”, vol. 43, pp. 4835–4846.en
dc.referencesSloan F.A., Hsieh C.-R. (2017), Health Economics, MIT Press, Cambridge.en
dc.referencesWHO (n.d.), Essential medicines, http://www.emro.who.int/health-topics/essential-medicines/index.html (accessed: 16.08.2021).en
dc.referencesWHO (n.d.), European Region Health Expenditure Dashboard, https://www.who.int/health_financing/topics/resource-tracking/European-Region-Health-Expenditure-Dashboard.pdf (accessed: 16.08.2021).en
dc.referencesWHO (n.d.), Global Essential Medicines, https://global.essentialmeds.org/dashboard/countries/97 (accessed: 16.08.2021).en
dc.referencesWHO (n.d.), Global Health Expenditure Database, https://apps.who.int/nha/database/Home/Index/en (accessed: 16.08.2021).en
dc.referencesWHO (n.d.), Global Health Expenditure Database. Health Expenditure Profile, https://apps.who.int/nha/database/country_profile/Index/en (accessed: 16.08.2021).en
dc.referencesWHO (n.d.), Health accounts, https://www.who.int/health-topics/health-accounts#tab=tab_1 (accessed: 16.08.2021).en
dc.referencesWHO (n.d.), Health budget, https://www.who.int/health-topics/health-budget#tab=tab_1 (accessed: 16.08.2021).en
dc.referencesWHO (n.d.), Pharmaceutical products, http://www.emro.who.int/health-topics/pharmaceutical-products/index.html (accessed: 16.08.2021).en
dc.referencesWHO (2000a), Guidelines for the regulatory assessment of medicinal products for use in self-medication, https://apps.who.int/iris/handle/10665/66154 (accessed: 16.08.2021).en
dc.referencesWHO (2000b), WHO report on cancer: setting priorities, investing wisely and providing care for all, Geneva.en
dc.referencesWHO (2001), WHO/WTO Workshop on Pricing and Financing of Essential Drugs, https://www.who.int/news/item/11-04-2001-who-wto-workshop-on-pricing-and-financing-of-essential-drugs (accessed: 25.08.2021).en
dc.referencesWHO (2013), Prequalification of medicines by WHO, https://www.who.int/news-room/fact-sheets/detail/prequalification-of-medicines-by-who (accessed: 16.08.2021).en
dc.referencesWHO (2018), WHO Report: Medicines reimbursement policies in Europe, Geneva.en
dc.referencesWHO (2019), WHO Report: Global spending on health: a world in transition, “WHO/HIS/HGF/HFWorkingPaper”, no. 19.4.en
dc.referencesWHO (2020), WHO Report: Global spending on health 2020: weathering the storm, Geneva.en
dc.referencesWHO (2021a), Cardiovascular diseases (CVDs), https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed: 30.07.2021).en
dc.referencesWHO (2021b), Primary health care, https://www.who.int/news-room/fact-sheets/detail/primary-health-care (accessed: 16.08.2021).en
dc.referencesXu K., Soucat A., Kutzin J., Brindley C., Maele N. van de, Touré H., Aranguren Garcia M., Li D., Barroy H., Flores G., Roubal T., Indikadahena C., Cherilova V., Siroka A. (2018), Public Spending on Health: A Closer Look at Global Trends, ”WHO/HIS/HGF/HF Working Paper”, no. 18.3, World Health Organization, Geneva.en
dc.contributor.authorEmailagata.zoltaszek@uni.lodz.pl
dc.identifier.doi10.18778/0208-6018.358.03
dc.relation.volume1


Files in this item

Thumbnail
Name:
32-58_Zoltaszek.pdf
Size:
1.246Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0